NCT05622058 2023-02-27
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Aileron Therapeutics, Inc.
Phase 1 Terminated
Aileron Therapeutics, Inc.
Millendo Therapeutics, Inc.
Fortis Memorial Research Institute
ProCertus BioPharm, Inc